1. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region.
- Author
-
Bazarbachi A, Azim HA, Alizadeh H, Aljurf M, Barista I, Chaudhri NA, Fahed Z, Fahmy OA, Ghavamzadeh A, Khalaf MH, Khatib S, Kutoubi A, Paydas S, Elayoubi HR, Zaatari G, Zawam HM, and Zelenetz AD
- Subjects
- Africa, Northern epidemiology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Evidence-Based Medicine, Gallium Radioisotopes, Hodgkin Disease diagnosis, Hodgkin Disease therapy, Humans, Incidence, Lymphoma epidemiology, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin therapy, Middle East epidemiology, Positron-Emission Tomography, Tomography, X-Ray Computed, United States, Arabs statistics & numerical data, Lymphoma diagnosis, Lymphoma therapy
- Abstract
In the Middle East and North Africa (MENA) region, cancer has many epidemiologic and clinical features that are different from those in the rest of the world. Additionally, the region has a relatively young population and large disparities in the availability of resources at diagnostic and treatment levels. A critical need exists for regional guidelines on cancer care, including those for lymphoid malignancies. A panel of lymphoma experts from MENA reviewed the 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non-Hodgkin's Lymphoma and Hodgkin Lymphoma and suggested modifications for the region that were discussed with the United States NCCN Lymphoma Panels. This article presents the consensus recommendations.
- Published
- 2010
- Full Text
- View/download PDF